Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Investors keep food...

    Investors keep food firms on warning over antibiotics

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-21T09:00:33+05:30  |  Updated On 17 Aug 2021 11:20 AM IST

    Resistance to antibiotics has been flagged as a major risk to public health and economic growth by policymakers and the investor action formed part of global efforts to fight back by curtailing their use in the food chain.


    LONDON: An investor group managing some $5 trillion said it was pleased with the steps taken by fast-food companies to cut the use of antibiotics in their products and will continue to monitor firms as its three-year-long engagement comes to an end.


    Resistance to antibiotics has been flagged as a major risk to public health and economic growth by policymakers and the investor action formed part of global efforts to fight back by curtailing their use in the food chain.


    Read Also: Sale of antibiotics, prescription drugs OTC; Court asks Government to reply


    Since launching its engagement in 2016, the Farm Animal Investment Risk and Return (FAIRR) coalition said it had engaged with 20 companies worth a combined $280 billion.


    The companies were asked to establish a policy to phase out routine, non-medical use of antibiotics across their supply chains; specify clear targets and timelines for implementation; and report more transparently on their activities.


    All the companies engaged now had a formal policy in place or were expected to release one soon, and some were even outpacing the demands of increasingly tougher local regulations, the report from FAIRR seen by Reuters showed.


    While they recognised the need to limit antibiotics use and were working to collect data on usage and supplier compliance with their policies, there remained more to do, it said, with little transparency on implementation, including poor disclosure around antibiotics use and auditing practices.


    Read Also: 80 more Fixed Dose Drugs including Antibiotics, Hypertension Combos Banned by Health Ministry


    While formally ending the group engagement, FAIRR said it would continue to track performance and could restart the group effort if companies stall on reform. Individual members of the group may also continue engaging directly with companies.


    "FAIRR will be looking at each company's reporting and disclosure on how they are implementing the policies and commitments they have made. If we see no progress in terms of implementation that could be grounds to re-engage formally," Jo Raven, engagement manager at FAIRR, told Reuters.


    "We also want to explore the issue in other ways. For example, FAIRR will be actively looking at the pharmaceutical companies that make antibiotics for animal feed."

    antibioticsantibiotics resistanceFAIRRFarm Animal Investment Risk and Returnfast food companyfood firmimplementationInvestorsJo RavenLondonpharmaceuticalPharmaceutical industryresistanceresistance to antibioticstransparency
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok